We are creating some awesome events for you. Kindly bear with us.

New CUHK Nanotech to Revolutionise Atherosclerotic Treatment

The blockage of blood vessels caused by atherosclerosis is a leading cause of stroke and ischemic heart disease. However, current treatments including surgery are invasive, while lipid-lowering drugs can only slow down disease progression. While gene regulation is an emerging therapeutic approach to atherosclerosis, the delivery of therapeutic gene cargoes to atherosclerotic plaques remains inefficient.

A team led by Professor Jonathan Choi Chung-hang, Associate Professor in the Faculty of Engineering’s Department of Biomedical Engineering at The Chinese University of Hong Kong (CUHK), has developed a novel RNA nanoparticle to offer a potentially safe, effective treatment for atherosclerosis.

Research has shown that this RNA nanoparticle can naturally target receptors of plaque cells for delivering genes to atherosclerotic plaques, while alleviating atherosclerosis by modulating genes related to atherogenesis, consequently reducing and stabilising plaque without inducing severe toxicity. It paves the way for the use of nucleic acid nanotechnology to treat cardiovascular diseases.

The research, a collaboration with Professor Tian Xiao-yu, Assistant Professor in the Faculty of Medicine’s School of Biomedical Sciences at CUHK, has recently been published in the international journal The Proceedings of the National Academy of Sciences (PNAS).

Limitations of existing treatments

Atherosclerosis is a form of chronic inflammation caused primarily by high blood lipid levels. Fat, cholesterol and immune cell build-ups on the arterial wall induce the formation of atherosclerotic plaques. These plaques either narrow the blood vessels, restricting blood flow or they burst, forming blood clots that block thinner arteries in the brain or heart. This can lead to a stroke or ischemic heart disease.

World Health Organisation (WHO) research shows that stroke and ischemic heart disease accounted for 11% and 16% respectively of global mortality in 2020. In Hong Kong, heart disease has been the third-leading cause of death since the 1960s.

While treatment does exist for atherosclerosis (it includes surgical procedures like balloon angioplasty and endarterectomy), they are invasive and inefficient in reducing multiple plaque sites. Administering lipid-lowering drugs such as statins is also a treatment, but they can only slow down disease progression.

Bypassing the bottleneck for gene delivery with nucleic acid nanotechnology

Gene regulation is an emerging therapeutic approach to atherosclerosis, but current technology for gene delivery to plaque remains inefficient. Existing atherosclerosis nanomedicines mostly employ cationic carriers to complex gene cargoes through electrostatic interactions for gene delivery into plaque cells.

However, these nanomedicines are often bulky, larger than 100 nm, meaning they can be rapidly filtered by the liver and spleen following an intravenous injection before they reach the plaque, and they are cationic which may induce cytotoxicity in the body.

By passing this bottleneck in gene delivery, the CUHK has applied nucleic acid nanotechnology to develop a new RNA nanoparticle for plaque delivery. This smaller spherical nanoparticle of about 70 nm in size includes a biocompatible iron oxide nanoparticle core and about 300 therapeutic microRNA-146a strands attached to the core’s surface.

Their solution can naturally enter plaque cells without the aid of cationic transfection agents, thereby facilitating the intracellular delivery of microRNA-146a.

Data from the experiments have shown that upon an intravenous injection into mice that bear atherosclerotic plaques, the new RNA nanoparticle can naturally target the receptors on plaque cells and preferentially enter macrophages and endothelial cells inside the plaque.

Alleviating atherosclerosis with intravenous injections of RNA nanostructures

Furthermore, experiments have shown that repeated injections of RNA nanoparticles into plaque-bearing mouse models not only regressed and stabilised atherosclerotic plaque but also downregulated genes related to immune response and vascular inflammation. After four weeks of treatment, there was no pronounced accumulation of RNA nanoparticles inside major internal organs, nor did it induce severe toxicity.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.

Send this to a friend